<p>Cytokinetics, Incorporated（纳斯达克代码：CYTK - 获取免费报告）董事 Wendell Wierenga 于 12 月 22 日星期一出售了 20,000 股 Cytokinetics 股票。股票的平均售价为 66.14 美元，总价值为 1,322,800.00 美元。出售后，该董事直接持有公司 32,444 股股票，价值为 2,145,846.16 美元。这笔交易代表其持股减少了 38.14%。该出售在向 SEC 提交的文件中披露，您可以通过此链接访问。</p>
<ul>
<li>分析师认为仍有机会投资 Edgewise，股价上涨 332%</li>
</ul>
<p>Wendell Wierenga 最近还进行了以下交易：</p>
<ul>
<li>在 10 月 27 日星期一，Wendell Wierenga 出售了 4,375 股 Cytokinetics 股票。股票的平均售价为 58.68 美元，总价值为 256,725.00 美元。</li>
</ul>
<h2>Cytokinetics 股票表现</h2>
<p>在周二的交易中，CYTK 股价下跌 2.31 美元，达到 63.29 美元。该公司交易了 2,911,496 股，而其平均交易量为 1,932,222 股。Cytokinetics, Incorporated 的 12 个月低点为 29.31 美元，12 个月高点为 70.98 美元。该公司的 50 日简单移动平均为 62.83 美元，200 日简单移动平均为 48.88 美元。公司的市值为 77.4 亿美元，市盈率为-10.06，贝塔值为 0.58。</p>
<ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
<p>Cytokinetics（纳斯达克代码：CYTK - 获取免费报告）最近于 11 月 5 日星期三发布了其财报。这家生物制药公司报告本季度每股收益为（1.54 美元），超出市场共识预期的（1.59 美元）0.05 美元。该公司本季度的收入为 194 万美元，而分析师预期为 605 万美元。在去年同期，该公司每股收益为（1.36 美元）。Cytokinetics 的季度收入同比增长 318.1%。作为一个整体，卖方分析师预计 Cytokinetics, Incorporated 在当前财年将发布-5.24 的每股收益。</p>
<h2>分析师评级变动</h2>
<p>多家研究分析师最近对该公司进行了评估。HC Wainwright 在周一的研究报告中将 Cytokinetics 的目标价从 120.00 美元上调至 136.00 美元，并给予该公司 “买入” 评级。美国银行在 10 月 2 日的报告中将 Cytokinetics 的目标价从 52.00 美元上调至 56.00 美元，并给予该公司 “中性” 评级。Leerink Partners 在周一的研究报告中设定了 Cytokinetics 的目标价为 83.00 美元。华尔街 Zen 在 11 月 8 日的研究报告中将 Cytokinetics 的评级从 “持有” 下调至 “卖出”。最后，Needham &amp; Company LLC 在周一将 Cytokinetics 的目标价从 72.00 美元上调至 84.00 美元，并给予该公司 “买入” 评级。十五家股票研究分析师对该股票给予了买入评级，三家给予了持有评级，一家给予了卖出评级。根据 MarketBeat 的数据，Cytokinetics 目前的平均评级为 “适度买入”，共识目标价为 83.61 美元。</p>
<p><strong>阅读我们关于 Cytokinetics 的最新股票报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。Hudson Bay Capital Management LP 在第三季度将其在 Cytokinetics 的持股增加了 15.4%。Hudson Bay Capital Management LP 现在拥有 182,131 股生物制药公司的股票，价值为 10,010,000 美元，此前在该期间内又购买了 24,345 股。瑞士人寿资产管理有限公司在第三季度购买了 Cytokinetics 的新股份，价值约为 283,000 美元。CIBC 私人财富集团在第三季度将其在 Cytokinetics 的持股增加了 8.1%。CIBC 私人财富集团现在拥有 3,484 股生物制药公司的股票，价值为 191,000 美元，此前在上个季度又购买了 261 股。CIBC Bancorp USA Inc.在第三季度购买了 Cytokinetics 的新头寸，价值约为 684,000 美元。最后，Coldstream Capital Management Inc.在第三季度购买了 Cytokinetics 的新头寸，价值约为 261,000 美元。</p>
<h2>Cytokinetics 新闻摘要</h2>
<p>以下是本周影响 Cytokinetics 的主要新闻：</p>
<ul>
<li>积极情绪：FDA 批准 MYQORZO 使 Cytokinetics 成为一家商业阶段公司，创造了新的心脏病学收入来源，并将投资者的关注从管道价值转向产品销售增长。阅读更多。</li>
<li>积极情绪：多家银行提高了目标价并重申了买入/超越表现的观点（巴克莱、摩根士丹利、Needham、Citizens JMP、美国银行），表明分析师信心恢复，并为投资者提供了向上的估值支撑。代表性文章：阅读更多，阅读更多，阅读更多。</li>
<li>积极情绪：分析师评论强调 MYQORZO 的标签优势（灵活剂量）相较于现有产品（Camzyos），管理层认为这可以推动超过 50% 的医生偏好和到 2026 年底的中高 20% 的市场渗透——如果采用达到目标，将支持多年的销售增长。阅读更多。</li>
<li>积极情绪：异常大的看涨期权活动（购买 5,619 个看涨期权，约 +103% 与正常相比）表明在批准消息前后存在投机性/对冲的看涨头寸。（市场期权流动报告于 12 月 22 日。）</li>
<li>中性情绪：公司管理层公开讨论了 FDA 批准和商业计划（转录覆盖可用）——对建模采用时间和启动成本有用，但不是立即的收入指标。阅读更多。</li>
<li>消极情绪：分析师的报告指出，采用可能是渐进的，并可能依赖于援助计划以达到渗透目标，这在推出阶段引入了执行和利润风险。阅读更多。</li>
</ul>
<h2>Cytokinetics 公司简介</h2>
<p>（获取免费报告）</p>
<p>细胞动力公司是一家处于后期阶段的生物制药公司，专注于发现和开发调节肌肉功能的新型小分子治疗药物。公司成立于 1998 年，总部位于加利福尼亚州南旧金山，利用其在肌肉生物学方面的专有见解来解决肌肉功能受损所导致的疾病。其研究涵盖心脏和骨骼肌靶点，旨在为具有显著未满足医疗需求的疾病提供创新药物。</p>
<p>该公司的最先进项目，奥美卡特（omecamtiv mecarbil），正在评估用于通过增强心脏肌肉收缩力来治疗心力衰竭。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比细胞动力更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在细胞动力吗？</h2>
<p>在考虑细胞动力之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而细胞动力并不在名单上。</p>
<p>虽然细胞动力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

细胞动力

<p>Cytokinetics 董事 Wendell Wierenga 出售了 20,000 股，交易金额为 1,322,800 美元，减少了 38.14% 的持股比例。此次出售在 SEC 文件中披露。该公司的股票表现和最近的收益也得到了强调，分析师们提供了混合的评级和价格目标。机构投资者在买卖股票方面表现活跃。最近 FDA 对 MYQORZO 的批准对公司的前景产生了积极影响</p>

<p>Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Wendell Wierenga sold 20,000 shares of Cytokinetics stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $66.14, for a total value of $1,322,800.00. Following the sale, the director directly owned 32,444 shares in the company, valued at $2,145,846.16. This trade represents a 38.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.</p>
<div class="lb-trans"><p>Cytokinetics, Incorporated（纳斯达克代码：CYTK - 获取免费报告）董事 Wendell Wierenga 于 12 月 22 日星期一出售了 20,000 股 Cytokinetics 股票。股票的平均售价为 66.14 美元，总价值为 1,322,800.00 美元。出售后，该董事直接持有公司 32,444 股股票，价值为 2,145,846.16 美元。这笔交易代表其持股减少了 38.14%。该出售在向 SEC 提交的文件中披露，您可以通过此链接访问。</p>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为仍有机会投资 Edgewise，股价上涨 332%</li>
</ul>
</div><p>Wendell Wierenga also recently made the following trade(s):</p>
<div class="lb-trans"><p>Wendell Wierenga 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, October 27th, Wendell Wierenga sold 4,375 shares of Cytokinetics stock. The stock was sold at an average price of $58.68, for a total value of $256,725.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 10 月 27 日星期一，Wendell Wierenga 出售了 4,375 股 Cytokinetics 股票。股票的平均售价为 58.68 美元，总价值为 256,725.00 美元。</li>
</ul>
</div><h2>Cytokinetics Stock Performance</h2>
<div class="lb-trans"><h2>Cytokinetics 股票表现</h2>
</div><p>CYTK traded down $2.31 during trading on Tuesday, reaching $63.29. 2,911,496 shares of the company traded hands, compared to its average volume of 1,932,222. Cytokinetics, Incorporated has a 12-month low of $29.31 and a 12-month high of $70.98. The firm has a fifty day simple moving average of $62.83 and a 200 day simple moving average of $48.88. The company has a market cap of $7.74 billion, a P/E ratio of -10.06 and a beta of 0.58.</p>
<div class="lb-trans"><p>在周二的交易中，CYTK 股价下跌 2.31 美元，达到 63.29 美元。该公司交易了 2,911,496 股，而其平均交易量为 1,932,222 股。Cytokinetics, Incorporated 的 12 个月低点为 29.31 美元，12 个月高点为 70.98 美元。该公司的 50 日简单移动平均为 62.83 美元，200 日简单移动平均为 48.88 美元。公司的市值为 77.4 亿美元，市盈率为-10.06，贝塔值为 0.58。</p>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
</div><p>Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, topping the consensus estimate of ($1.59) by $0.05. The company had revenue of $1.94 million during the quarter, compared to analysts' expectations of $6.05 million. During the same period last year, the firm posted ($1.36) EPS. Cytokinetics's quarterly revenue was up 318.1% compared to the same quarter last year. As a group, sell-side analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Cytokinetics（纳斯达克代码：CYTK - 获取免费报告）最近于 11 月 5 日星期三发布了其财报。这家生物制药公司报告本季度每股收益为（1.54 美元），超出市场共识预期的（1.59 美元）0.05 美元。该公司本季度的收入为 194 万美元，而分析师预期为 605 万美元。在去年同期，该公司每股收益为（1.36 美元）。Cytokinetics 的季度收入同比增长 318.1%。作为一个整体，卖方分析师预计 Cytokinetics, Incorporated 在当前财年将发布-5.24 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts have recently weighed in on the company. HC Wainwright raised their price objective on Cytokinetics from $120.00 to $136.00 and gave the company a &#34;buy&#34; rating in a research report on Monday. Bank of America raised their price target on Cytokinetics from $52.00 to $56.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, October 2nd. Leerink Partners set a $83.00 price objective on Cytokinetics in a research note on Monday. Wall Street Zen downgraded Cytokinetics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 8th. Finally, Needham &amp; Company LLC raised their target price on shares of Cytokinetics from $72.00 to $84.00 and gave the company a &#34;buy&#34; rating in a report on Monday. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Cytokinetics currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $83.61.</p>
<div class="lb-trans"><p>多家研究分析师最近对该公司进行了评估。HC Wainwright 在周一的研究报告中将 Cytokinetics 的目标价从 120.00 美元上调至 136.00 美元，并给予该公司 “买入” 评级。美国银行在 10 月 2 日的报告中将 Cytokinetics 的目标价从 52.00 美元上调至 56.00 美元，并给予该公司 “中性” 评级。Leerink Partners 在周一的研究报告中设定了 Cytokinetics 的目标价为 83.00 美元。华尔街 Zen 在 11 月 8 日的研究报告中将 Cytokinetics 的评级从 “持有” 下调至 “卖出”。最后，Needham &amp; Company LLC 在周一将 Cytokinetics 的目标价从 72.00 美元上调至 84.00 美元，并给予该公司 “买入” 评级。十五家股票研究分析师对该股票给予了买入评级，三家给予了持有评级，一家给予了卖出评级。根据 MarketBeat 的数据，Cytokinetics 目前的平均评级为 “适度买入”，共识目标价为 83.61 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Cytokinetics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Cytokinetics 的最新股票报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP boosted its stake in Cytokinetics by 15.4% during the third quarter. Hudson Bay Capital Management LP now owns 182,131 shares of the biopharmaceutical company's stock worth $10,010,000 after buying an additional 24,345 shares during the period. Swiss Life Asset Management Ltd bought a new stake in shares of Cytokinetics in the 3rd quarter worth about $283,000. CIBC Private Wealth Group LLC lifted its holdings in shares of Cytokinetics by 8.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 3,484 shares of the biopharmaceutical company's stock worth $191,000 after acquiring an additional 261 shares during the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Cytokinetics during the 3rd quarter worth about $684,000. Finally, Coldstream Capital Management Inc. bought a new position in Cytokinetics during the 3rd quarter valued at about $261,000.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该公司的股票。Hudson Bay Capital Management LP 在第三季度将其在 Cytokinetics 的持股增加了 15.4%。Hudson Bay Capital Management LP 现在拥有 182,131 股生物制药公司的股票，价值为 10,010,000 美元，此前在该期间内又购买了 24,345 股。瑞士人寿资产管理有限公司在第三季度购买了 Cytokinetics 的新股份，价值约为 283,000 美元。CIBC 私人财富集团在第三季度将其在 Cytokinetics 的持股增加了 8.1%。CIBC 私人财富集团现在拥有 3,484 股生物制药公司的股票，价值为 191,000 美元，此前在上个季度又购买了 261 股。CIBC Bancorp USA Inc.在第三季度购买了 Cytokinetics 的新头寸，价值约为 684,000 美元。最后，Coldstream Capital Management Inc.在第三季度购买了 Cytokinetics 的新头寸，价值约为 261,000 美元。</p>
</div><h2>Cytokinetics News Summary</h2>
<div class="lb-trans"><h2>Cytokinetics 新闻摘要</h2>
</div><p>Here are the key news stories impacting Cytokinetics this week:</p>
<div class="lb-trans"><p>以下是本周影响 Cytokinetics 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: FDA approval of MYQORZO turns Cytokinetics into a commercial-stage company, creating a new cardiology revenue stream and shifting investor focus from pipeline value to product sales growth. Read More.</li>
<li>Positive Sentiment: Several banks raised price targets and reiterated buy/outperform views (Barclays, Morgan Stanley, Needham, Citizens JMP, BofA), signaling refreshed analyst conviction and giving investors upward valuation anchors. Representative articles: Read More., Read More., Read More.</li>
<li>Positive Sentiment: Analyst commentary highlights MYQORZO’s label advantages (flexible dosing) versus the incumbent (Camzyos), which management believes can drive &gt;50% physician preference and mid‑high 20% category penetration by end‑2026 — supporting a multi‑year sales ramp if adoption meets targets. Read More.</li>
<li>Positive Sentiment: Unusually large call‑option activity (5,619 calls bought, roughly +103% vs. normal) indicates speculative/hedged bullish positioning ahead of/after the approval news. (Market options flow reported 12/22.)</li>
<li>Neutral Sentiment: Company management publicly discussed the FDA approval and commercial plans (transcript coverage available) — useful for modeling uptake timing and launch costs but not an immediate revenue read. Read More.</li>
<li>Negative Sentiment: Analyst writeups note adoption may be gradual and could rely on assistance programs to reach penetration targets, which introduces execution and margin risk during the launch phase. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：FDA 批准 MYQORZO 使 Cytokinetics 成为一家商业阶段公司，创造了新的心脏病学收入来源，并将投资者的关注从管道价值转向产品销售增长。阅读更多。</li>
<li>积极情绪：多家银行提高了目标价并重申了买入/超越表现的观点（巴克莱、摩根士丹利、Needham、Citizens JMP、美国银行），表明分析师信心恢复，并为投资者提供了向上的估值支撑。代表性文章：阅读更多，阅读更多，阅读更多。</li>
<li>积极情绪：分析师评论强调 MYQORZO 的标签优势（灵活剂量）相较于现有产品（Camzyos），管理层认为这可以推动超过 50% 的医生偏好和到 2026 年底的中高 20% 的市场渗透——如果采用达到目标，将支持多年的销售增长。阅读更多。</li>
<li>积极情绪：异常大的看涨期权活动（购买 5,619 个看涨期权，约 +103% 与正常相比）表明在批准消息前后存在投机性/对冲的看涨头寸。（市场期权流动报告于 12 月 22 日。）</li>
<li>中性情绪：公司管理层公开讨论了 FDA 批准和商业计划（转录覆盖可用）——对建模采用时间和启动成本有用，但不是立即的收入指标。阅读更多。</li>
<li>消极情绪：分析师的报告指出，采用可能是渐进的，并可能依赖于援助计划以达到渗透目标，这在推出阶段引入了执行和利润风险。阅读更多。</li>
</ul>
</div><h2>Cytokinetics Company Profile</h2>
<div class="lb-trans"><h2>Cytokinetics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.</p>
<div class="lb-trans"><p>细胞动力公司是一家处于后期阶段的生物制药公司，专注于发现和开发调节肌肉功能的新型小分子治疗药物。公司成立于 1998 年，总部位于加利福尼亚州南旧金山，利用其在肌肉生物学方面的专有见解来解决肌肉功能受损所导致的疾病。其研究涵盖心脏和骨骼肌靶点，旨在为具有显著未满足医疗需求的疾病提供创新药物。</p>
</div><p>The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.</p>
<div class="lb-trans"><p>该公司的最先进项目，奥美卡特（omecamtiv mecarbil），正在评估用于通过增强心脏肌肉收缩力来治疗心力衰竭。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Cytokinetics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比细胞动力更好的股票</li>
<li>请勿删除，立即阅读</li>
<li>投资者警报：微型 “$3 AI 奇迹股票” 即将腾飞</li>
<li>是否可以从资本利得税中扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1lUSw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=CYTK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cytokinetics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在细胞动力吗？</h2>
</div><p>Before you consider Cytokinetics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑细胞动力之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytokinetics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而细胞动力并不在名单上。</p>
</div><p>While Cytokinetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然细胞动力目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

细胞动力（NASDAQ:CYTK）的一位董事出售了价值 1,322,800.00 美元的股票